Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115605

Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor.

Y K Fu, S Arkins, G Fuh, B C Cunningham, J A Wells, S Fong, M J Cronin, R Dantzer, and K W Kelley

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Fu, Y. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Arkins, S. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Fuh, G. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Cunningham, B. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Wells, J. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Fong, S. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Cronin, M. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Dantzer, R. in: JCI | PubMed | Google Scholar

Department of Animal Sciences, University of Illinois, Urbana 61801.

Find articles by Kelley, K. in: JCI | PubMed | Google Scholar

Published February 1, 1992 - More info

Published in Volume 89, Issue 2 on February 1, 1992
J Clin Invest. 1992;89(2):451–457. https://doi.org/10.1172/JCI115605.
© 1992 The American Society for Clinical Investigation
Published February 1, 1992 - Version history
View PDF
Abstract

Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O2-) secretion. Since HuGH, but not GH of other species, effectively binds to the HuPRL receptor (HuPRL-R), we used a group of HuGH variants created by site-directed mutagenesis to identify the receptor on human neutrophils responsible for HuGH priming. A monoclonal antibody (MAb) directed against the HuPRL-R completely abrogated O2- secretion by neutrophils incubated with either HuGH or HuPRL, whereas a MAb to the HuGH-R had no effect. The HuGH variant K172A/F176A, which has reduced affinity for both the HuGH-binding protein (BP) and the HuPRL-BP, was unable to prime human neutrophils. This indicates that priming is initiated by a ligand-receptor interaction, the affinity of which is near that defined for receptors for PRL and GH. Another HuGH variant, K168A/E174A, which has relatively low affinity for the HuPRL-BP but slightly increased affinity for the HuGH-BP, had much reduced ability to prime neutrophils. In contrast, HuGH variant E56D/R64M, which has a similar affinity as wild-type HuGH for the HuPRL-BP but a lower affinity for the HuGH-BP, primed neutrophils as effectively as the wild-type HuGH. Finally, binding of HuGH to the HuPRL-BP but not to the HuGH-BP has been shown to be zinc dependent, and priming of neutrophils by HuGH was also responsive to zinc. Collectively, these data directly couple the binding of HuGH to the HuPRL-R with one aspect of functional activation of human target cells.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 451
page 451
icon of scanned page 452
page 452
icon of scanned page 453
page 453
icon of scanned page 454
page 454
icon of scanned page 455
page 455
icon of scanned page 456
page 456
icon of scanned page 457
page 457
Version history
  • Version 1 (February 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts